MedTech Business - January 3, 2017
First delivery of Nevisense View for SciBase
SciBase’s new instrument Nevisense View which combines patented impedance measurement (EIS) for early detection of malignant melanoma with visual information from digital dermoscopy, has left SciBase for delivery to Belgium. The new instrument Nevisense View integrates images from digital dermoscopy with Nevisense’s EIS-technology. The result is that all information from a skin examination is gathered […]
New Market - December 21, 2016
Orion plans for a new market authorisation
Orion Corporation has received favorable pharmacokinetic study results with combined salmeterol-fluticasone formulation of the Easyhaler product family and based on the results Orion is planning to apply for a marketing authorisation for the product in Europe. Orion currently estimates that the marketing authorisation application could be submitted in Europe during the first half of 2017. […]
MedTech Business - August 29, 2016
BrainCool to the Japanese market
Swedish BrainCool signs distribution agreement for Japanese market with FINGAL Link Co. Ltd. The distribution agreement concerns their product The BrainCool System and during this fall market preparations will be made. FINGAL Link is a strong local company with both products of their own as well as international products which they distribute. The company is […]
New Market - March 16, 2016
SenzaGen establishes subsidiary in the US
To quickly strengthen its commercial presence in the US market, Swedish SenzaGen AB expands globally and establishes a subsidiary in California. SenzaGen, which develops and implements non-animal allergy tests of chemicals and proteins, for the chemical, pharmaceutical and cosmetic industries, expands its sales organization and prepares the company for an IPO in 2017. Senzagen, a […]
New Market - January 5, 2016
Oasmia applies for market approval in Russia
Swedish Oasmia Pharmaceutical has submitted an application for marketing approval of Doxophos for Russia and the Commonwealth of the Independent States (CIS). The company expects market approval of Doxophos by the end of 2016. Doxophos is a hybrid and novel nanoparticle formulation of one of the most commonly used anti-cancer substances in the world, doxorubicin. […]
New Market - November 23, 2015
XVIVO’s product approved in China
XVIVO Perfusion has received approval of its STEEN Solution by the China Food and Drug Administration (CFDA). This decision enables the company to market and sell STEEN Solution for clinical use in China. CFDA has approved STEEN Solution for lung transplantation, which allows sales of STEEN Solution for clinical use in lung transplants in China. […]
